PARP Inhibitors and Haematological Malignancies—Friend or Foe?
Since their introduction several years ago, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have become the standard of care for breast and gynaecological cancers with <i>BRCA</i> gene mutations. Given that PARPi act by exploiting defective DNA repair mechanisms within tumour cell...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/21/5328 |